ROS1 and adenocarcinoma: Patients with low PD-L1 expression in adenocarcinoma had longer OS than those with high expression.28,29 ROS1 fusion genes, present in various tumors, promote cell proliferation, activation, and cell cycle progression by activating downstream signaling pathways, accelerating NSCLC development and progression.